Frontiers | Comparative evaluation of clinical glycemic control markers ...
The study evaluates imeglimin's effect on type 2 diabetes patients, focusing on HbA1c, GA, and 1,5-AG as glycemic control markers. It examines imeglimin's impact on erythrocytes, hypothesizing prolonged erythrocyte lifespan may affect HbA1c accuracy. The study also explores imeglimin's potential in treating peripheral arterial disease by improving erythrocyte deformability.
Reference News
The study evaluates imeglimin's effect on type 2 diabetes patients, focusing on HbA1c, GA, and 1,5-AG as glycemic control markers. It examines imeglimin's impact on erythrocytes, hypothesizing prolonged erythrocyte lifespan may affect HbA1c accuracy. The study also explores imeglimin's potential in treating peripheral arterial disease by improving erythrocyte deformability.